Research programme: Nanobodies - Ablynx

Drug Profile

Research programme: Nanobodies - Ablynx

Alternative Names: ABX-0401; ABX-0402; ABX-0403; ALX-0962 (anti-IgE antibody); Anti-IgE Nanobody; Anti-TNF Nanobodies; Anti-VWF Nanobody

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ablynx
  • Class Proteins
  • Mechanism of Action IgE receptor antagonists; Immunomodulators; Interleukin 6 receptor modulators; RANK ligand inhibitors; Von Willebrand factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thrombotic thrombocytopenic purpura
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Allergic asthma; Autoimmune disorders; Bone disorders; Cancer; Infections; Inflammation; Respiratory syncytial virus infections; Respiratory tract disorders; Thrombotic thrombocytopenic purpura

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Allergic-asthma in Belgium (Parenteral, Controlled release)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in Belgium (Parenteral, Injection)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bone-disorders in Belgium (Parenteral, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top